You are here

Ibrance

In mysterious FDA approval, Pfizer quietly wins Ibrance breast cancer expansion

In mysterious FDA approval, Pfizer quietly wins Ibrance breast cancer expansion

Fierce Pharma

Flag link:

Pfizer and Erasca Target Pancreatic, Colorectal Cancer with "Synergistic" Pairing

Pfizer and Erasca Target Pancreatic, Colorectal Cancer with "Synergistic" Pairing

BioSpace

colorectal cancer

Flag link:

Pfizer's Ibrance Fails to Significantly Extend Lives of Breast Cancer Patients

Pfizer's Ibrance Fails to Significantly Extend Lives of Breast Cancer Patients

BioSpace

HER2-negative breast cancer

Flag link:

ASCO: Pfizer's Ibrance fails to extend lives in newly diagnosed breast cancer. Will doctors switch gears to Novartis, Lilly?

ASCO: Pfizer's Ibrance fails to extend lives in newly diagnosed breast cancer. Will doctors switch gears to Novartis, Lilly?

Fierce Pharma

HER2-negative breast cancer

clinical trials

Flag link:

Bristol Myers Squibb, Amgen and Pfizer approach steepest patent cliffs among large drugmakers

Bristol Myers Squibb, Amgen and Pfizer approach steepest patent cliffs among large drugmakers

Fierce Pharma

Bristol Myers Squibb

Flag link:

ESMO: Syros targets KRAS-mutant cancer as CDK7 inhibitor shows early promise

ESMO: Syros targets KRAS-mutant cancer as CDK7 inhibitor shows early promise

Fierce Biotech

Syros Pharmaceuticals

Flag link:

Pfizer's Ibrance, under threat from Novartis and Lilly, leans on real-world data in breast cancer

Pfizer's Ibrance, under threat from Novartis and Lilly, leans on real-world data in breast cancer

Fierce Pharma

Flag link:

Immuno-Oncology Treatments Finding Success with Combination Therapies

Immuno-Oncology Treatments Finding Success with Combination Therapies

BioSpace

immuno-oncology

Bristol-Myers Squibb

clinical trials

Flag link:

Ibrance trial failure dashes Pfizer’s growth hopes for the drug

Ibrance trial failure dashes Pfizer’s growth hopes for the drug

Pharmaforum

Flag link:

Pfizer's breast cancer drug Ibrance fails late-stage study

Pfizer's breast cancer drug Ibrance fails late-stage study

Reuters

clinical trials

Flag link:

ESMO: Lilly's Verzenio pressures Pfizer with practice-changing win in early breast cancer

ESMO: Lilly's Verzenio pressures Pfizer with practice-changing win in early breast cancer

Fierce Pharma

Flag link:

Cut-price drug venture takes aim at Pfizer and Astrazeneca

Cut-price drug venture takes aim at Pfizer and Astrazeneca

EP Vantage

Flag link:

Pfizer's Ibrance misses shot at big new market with early breast cancer failure

Pfizer's Ibrance misses shot at big new market with early breast cancer failure

Fierce Pharma

clinical trials

HER2-negative breast cancer

Flag link:

Three Breast Cancer Drugs: FDA Warns of Rare but Serious Lung Inflammation

Three Breast Cancer Drugs: FDA Warns of Rare but Serious Lung Inflammation

RAPS.org

Flag link:

Pfizer points to newer meds—including Ibrance—as post-Upjohn cash engines

Pfizer points to newer meds—including Ibrance—as post-Upjohn cash engines

Fierce Pharma

Flag link:

FDA Approves Pfizer’s Ibrance in Men With Breast Cancer

FDA Approves Pfizer’s Ibrance in Men With Breast Cancer

BioSpace

male breast cancer

Flag link:

Pfizer works to get 'wait-and-see' doctors on board the Ibrance train

Pfizer works to get 'wait-and-see' doctors on board the Ibrance train

Fierce Pharma

Flag link:

NICE spurns Lilly’s breast cancer drug Verzenio in favor of rivals from Pfizer and Novartisspir

NICE spurns Lilly’s breast cancer drug Verzenio in favor of rivals from Pfizer and Novartisspir

Fierce Pharma

Flag link:

A slowing market—not new rivals—is hurting Pfizer's star cancer drug Ibrance, executives say

A slowing market—not new rivals—is hurting Pfizer's star cancer drug Ibrance, executives say

Fierce Pharma

Flag link:

Pages